BiomarkersHumans
Performance of the Lumipulse plasma p ‐tau217 assay to assess eligibility for amyloid‐lowering therapies
AAIC 2025 Abstract
Abstract
Background: Clinically available plasma p ‐tau217 assays may be utilized in the determination of eligibility for amyloid‐lowering therapies.
The paper
Alicia Algeciras‐Schimnich, Susan Ashrafzadeh‐Kian, Joshua A. Bornhorst, Vijay K. Ramanan
Show 7 more authors
Daniel J. Figdore, Brian J. Burkett, Petrice M. Cogswell, Derek Richard Johnson, Stuart J. McCarter, Jonathan Graff‐Radford, Ronald Petersen,Mayo Clinic
AAIC 2025 Abstract · 24 Dec 2025 · CC BY
Presented at AAIC 2025
